Supplementary Figure 7 from An Antibody That Locks HER3 in the Inactive Conformation Inhibits Tumor Growth Driven by HER2 or Neuregulin
Year: 2023
Type: supplementary-materials
Abstract: PDF file - 1205K, Figure S7. Treatment of HER2 amplified cell lines with LJM716/ trastuzumab combinations is synergistic in a subset of cell lines.
Authors: Andrew P. Garner, Carl U. Bialucha, Elizabeth R. Sprague, Joan T. Garrett, Qing Sheng, Sharon Li, Olga Sineshchekova, Parmita Saxena, Cammie R. Sutton, Dongshu Chen, Yan Chen, Huiqin Wang, Jinsheng Liang, Rita Das, Rebecca Mosher, Jian Gu, Alan Huang, Nicole Haubst, Carolin Zehetmeier, Manuela Haberl, Winfried Elis, Christian Kunz, Analeah B. Heidt, Kara Herlihy, Joshua Murtie, Alwin Schuller, Carlos L. Arteaga, William R. Sellers, Seth A. Ettenberg
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362459532